Hey everyone! In this video, I discuss the relationship history between Amarin and the FDA regarding their EPA medication (Vascepa) for the lowering of triglycerides. I believe the difficulty #AMRN has had with the FDA in the past has made the market concerned about Vascepa’s future given recent announcement of an advisory committee meeting for label expansion of Vascepa. I also talk about Sarepta, Novartis and Gilead. Thanks for watching!
For my previous analysis of Amarin, check out #034.
*This is not investment advice. Please do your own due diligence before ever investing in equity markets.*
Great resource on Amarin’s approval issues with the FDA